Clinical reports

March 01, 2022 | Download PDF

Drug and Biologic Pipeline Q2 2023

This quarterly newsletter provides information about upcoming Food and Drug Administration (FDA) approvals. 

Drug and Biologic Pipeline Q2 2023

CarelonRx Specialty Conditions Value of Integration Study

Discover how medical and pharmacy benefit integration drives savings.

CarelonRx Specialty Conditions Value of Integration Study

DrugInsights Q1 2023

This quarterly update summarizes (FDA)-approved new molecular entities, formulations, and indications. 

DrugInsights Q1 2023

Drug and Biologic Pipeline Q1 2023

This quarterly newsletter provides information about upcoming Food and Drug Administration (FDA) approvals. 

Drug and Biologic Pipeline Q1 2023

Drug Insights Q4-2022

IngenioRx’s DrugInsights provides a quarterly summary of Food and Drug Administration (FDA)-approved new molecular...

Drug Insights Q4-2022

Drug + Biologic Pipeline Q4 2022

We publish the IngenioRx Drug and Biologic Pipeline Update each quarter to keep you informed about upcoming FDA approvals.

Drug + Biologic Pipeline Q4 2022

IngenioRx Drug Insights Q3 2022

IngenioRx’s Q3 2022 DrugInsights provides a quarterly summary of Food and Drug Administration (FDA)-approved new...

IngenioRx Drug Insights Q3 2022

Drug + Biologic Pipeline Q3 2022

IngenioRx closely monitors drugs, biologics, and gene therapies in development. Our Q3 2022 IngenioRx Drug and Biologic Pipeline...

Drug + Biologic Pipeline Q3 2022

2021 IngenioRx Drug Trend Report*

How did we keep trend and spend down despite the effects of utilization, inflation, and new drugs introduced to the market?   

2021 IngenioRx Drug Trend Report*

Drug Insights Q2 2022

IngenioRx’s DrugInsights provides a quarterly summary of Food and Drug Administration (FDA)-approved new molecular...

Drug Insights Q2-2022*

Drug + Biologic Pipeline Q2 2022

We publish the IngenioRx Drug and Biologic Pipeline Update each quarter to keep our audiences informed about upcoming Food...

Drug + Biologic Pipeline Q2 2022

Drug Insights Q1-2022

IngenioRx’s DrugInsights provides a quarterly summary of Food and Drug Administration (FDA)-approved new molecular...

Drug Insights Q1-2022

*Today, we are CarelonRx, but when we created some of these documents, we were IngenioRx. This name change doesn’t impact our dedication to driving cost savings, personalizing customer experiences, and improving whole-person health.